Hutchison China MediTech: Q2 2014 Results (Hutchison China MediTech) - Aug 6, 2014 - "HMPL-004"; "Ulcerative Colitis Phase III Interim Analysis"; "Strong HMPL-004 Phase IIb data in UC...but high placebo,(historically common in IBD)"; "Baseline patient: 7-9 Modified Mayo Score (out of 12): 3+ stools/day (last 5-7 days), Blood w/stool. Serious abnormalities"; "Remission patient: 0-2 Modified Mayo Score (out of 12): Normal stools/day (last 5-7 days), No blood seen. Mild symptoms" "
P2 data • Immunology • Inflammatory Bowel Disease
|